

Supplementary Table 2: Learning session content for shared learning and feedback during the Neonatal Antimicrobial Stewardship (NeoAMS) study

<p>NeoAMS</p> <p>LEARNING SESSION 1</p> <p>3 Feb 2022</p>	<ul style="list-style-type: none"> • Welcome, introduction of multidisciplinary participants & study faculty. • Introducing the field of collective enquiry a brief overview of the different stages of the study. • Short videos by study faculty and study leaders on the importance of the study in the SA national antibiotic stewardship context and on the opportunity to collaborate with the US study partners. • An introduction to improvement methodology and the design of the study. • Roadmap of the journey ahead. • Introduction to the Baseline Situational Analysis (BSA) rationale and what is required. • Overview of the content of the standardised data collection template for the BSA. • How to access and use the RedCap electronic data collection tool for the BSA. • Q&A session on data collection and interpretation of the BSA criteria. • Checklist of essential activities to be completed during the Action Period by the required deadlines. • How to complete the standardised slides for the next session with photos for the “meet the team members at each hospital” session including why they are each excited about the study.
<p>NeoAMS</p> <p>LEARNING SESSION 2</p> <p>17 Feb 2022</p>	<ul style="list-style-type: none"> • Welcome and check in by participating teams using meet the team standardised slides - • Quick recap of methodology and what was completed and what is next. • Introduction by expert faculty on the importance of qualitative research in AMS and the essential concepts of barriers and enablers in AMS. • Overview of the basis of the Barriers and Enablers Survey (BES). • Detailed review of the different sections, questions and measures for the BES as well as who to include in the survey. • Standardised email for distribution to survey participants. • How to access and use the RedCap electronic data collection tool for the BES.. • Q&A session on data collection and interpretation of the BSA criteria. • Checklist of essential activities for next steps and timelines for next phase.
<p>NeoAMS</p> <p>LEARNING SESSION 3</p> <p>15 Mar 2022</p>	<ul style="list-style-type: none"> • Welcome and check in by teams and faculty. • Update on BSA completed and what is outstanding. • Update on BES completed by different categories of the multidisciplinary team. • Introduction to the NeoAMS interventions and the audit and feedback process and multidisciplinary team engagement process. • Video interviews by expert study faculty of <ul style="list-style-type: none"> - Pharmacist role - Clinical Microbiologists role - Neonatal clinician role - Neonatal nurse role - US collaborators clinical experience in the study interventions • Neonatal AMS papers (x5) distributed to all participants for reading. • Launch of the 2-week pilot intervention to test the process and become familiar with the standardised electronic tool for data collection. • Pharmacists attended a separate detailed session on how to use the standardised RedCap tool. • Key issues to watch out for regarding data submission and process for improvement of the standardised tool and RedCap data capturing tool. • Q&A on pilot intervention phase. • Faculty support details for any problems or questions during the pilot intervention phase. • Checklist of essential activities for next steps and timelines for next phase.
<p>NeoAMS</p> <p>LEARNING SESSION 4</p> <p>29 Mar 2022</p>	<ul style="list-style-type: none"> • Welcome and check in • Update on BSA and BES elements. • Explanation of Antibiogram criteria raised during Q&A with literature provided. • High level Zoom chat interaction on how pilot intervention has gone including the multidisciplinary team (MDT) engagement. • Detailed per hospital feedback and shared learning on the AMS interventions, RedCap data capture, team meetings and issues needing clarification. • Q&A on interpretation of interventions and data collection. • Reminder of faculty support details for any problems or questions during the next intervention phase. • Run through of feedback slides for session 5. • Checklist of essential activities for next steps and timelines for next phase
<p>NeoAMS</p> <p>LEARNING SESSION 5</p>	<ul style="list-style-type: none"> • Welcome and check in • Update on collated data from all hospitals over past 4 weeks <ul style="list-style-type: none"> ○ number of neonates seen ○ interventions ○ feedback on MDT meetings.

<p>12 April 2022</p>	<ul style="list-style-type: none"> • By hospital feedback using standardised questions and slides – ‘Learning from, cheering for and inspiring each other • 3 Slides with Standardised questions • Slide 1 <ul style="list-style-type: none"> ○ Number of patients seen ○ Number of team meetings held so far – ○ Most common AMS interventions so far – ○ State any systems changes you may have implemented as a team • Slide 2 <ul style="list-style-type: none"> ○ Benefits and challenges of working as a MDT. • Slide 3 <ul style="list-style-type: none"> ○ Anything else you'd like to share • Questions for study faculty to cover in next session
<p>NeoAMS</p> <p>LEARNING SESSION 6</p> <p>9 June 2022</p>	<ul style="list-style-type: none"> • Welcome and check in • Faculty responses to questions from feedback slide 3 of session 5 and those sent in from field over the next four weeks. • Presentation on first level of collated data of the BES and BSA data. • Feedback on collated numbers of patients seen. • QI refresher on improvement methods and the importance of having a strong WHY to sustain our work. • By hospital feedback using standardised questions and slides – ‘Learning from, cheering for and inspiring each other • Slide 1 <ul style="list-style-type: none"> ○ As for session 5 • Slide 2 – Reaching for the summit. <ul style="list-style-type: none"> ○ What is still needed to reach your goals? ○ Gains since last feedback ○ Key learnings as a team since began the journey ○ Obstacles and setbacks experienced ○ What improvements have you experienced from working as a team • Slide 3 What opportunities for improvement do you see as: <ul style="list-style-type: none"> ○ A pharmacist ○ A neonatal nurse ○ Neonatal clinician ○ Clinical Microbiologist? • Slide 4 • Questions for study faculty to cover in next session
<p>NeoAMS</p> <p>LEARNING SESSION 7</p> <p>19 July 2022</p>	<ul style="list-style-type: none"> • Welcome and check in • Recap of the journey so far with key milestones • Next steps in the study and invitation to participate in Exit interviews as part of the qualitative research. • By hospital feedback using standardised questions and slides:- ‘Learning from, cheering for and inspiring each other • Slide 1 <ul style="list-style-type: none"> ○ As for session 5 and 6 • Slide 2 – Reaching the summit. <ul style="list-style-type: none"> ○ Biggest gains since starting the study. ○ What have the biggest obstacles or challenges been? ○ What benefits and learning did you experience from being part of the larger collaborative? ○ What further opportunities do you see for neonatal AMS in your hospital? • Slide 3: How has this study helped you expand/adjust your role in neonatal AMS in your hospital? <ul style="list-style-type: none"> ○ Pharmacist/s ○ Neonatal nurse/s ○ Neonatal clinician/s ○ Clinical Microbiologist/s? • Slide 4 <ul style="list-style-type: none"> ○ What obstacles and setbacks have you been able to deal with or overcome since we started the study ○ What plans do you have to sustain the progress and take NeoAMS forward? ○ What worked well for you in this study? ○ What improvements would you suggest for this study?

NeoAMS: Neonatal Antimicrobial Stewardship Study